Ciprofloxacin
- Generic Name
- Ciprofloxacin
- Brand Names
- Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18FN3O3
- CAS Number
- 85721-33-1
- Unique Ingredient Identifier
- 5E8K9I0O4U
- Background
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
The first ciprofloxacin containing product was FDA approved on 22 October 1987.
- Indication
Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...
- Associated Conditions
- Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae
- Associated Therapies
- -
Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT04147260
- Locations
- ๐บ๐ธ
TKL Research, Inc., Fair Lawn, New Jersey, United States
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 463
- Registration Number
- NCT04110340
- Locations
- ๐ฒ๐ฌ
Professor Mamy Randria, Antananarivo, Madagascar
Ciprofloxacin Plus Metronidazole Vs Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2019-07-22
- Target Recruit Count
- 140
- Registration Number
- NCT03969758
- Locations
- ๐ฎ๐ณ
Post Graduate Institute of Medical Education and Research, Chandigarh, India
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- CR-CSSS Champlain-Charles-Le Moyne
- Target Recruit Count
- 255
- Registration Number
- NCT03862170
- Locations
- ๐จ๐ฆ
Hรดpital Charles LeMoyne, Greenfield Park, Quebec, Canada
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-06-07
- Target Recruit Count
- 364
- Registration Number
- NCT03854929
- Locations
- ๐ป๐ณ
Children's Hospital 2, Ho Chi Minh City, Vietnam
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 308
- Registration Number
- NCT03850379
- Locations
- ๐บ๐ธ
Henry Ford, Detroit, Michigan, United States
Experimental Human Infection With Neisseria Gonorrhoeae
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-03-23
- Target Recruit Count
- 27
- Registration Number
- NCT03840811
- Locations
- ๐บ๐ธ
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States
Antibiotic Prophylaxis Before Shock Wave Lithotripsy
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Clinical Urology and Epidemiology Working Group
- Target Recruit Count
- 1500
- Registration Number
- NCT03692715
- Locations
- ๐ท๐บ
St Petersburg State Pavlov Medical University, Saint Petersburg, Russian Federation
๐ธ๐ฆKing Abdulaziz University, Jeddah, Saudi Arabia
๐จ๐ญDepartment of Urology, University Hospital Basel, Basel, Switzerland
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Recruiting
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธAnn and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธLoma Linda University Health, Loma Linda, California, United States
Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 10
- Registration Number
- NCT03476317
- Locations
- ๐บ๐ธ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath